1202760-30-2

Basic information

• Product Name: tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate
• Synonyms: tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate
• CAS NO: 1202760-30-2
• Molecular Weight: 399.675
• Mol File: 1202760-30-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate(1202760-30-2)
• EPA Substance Registry System: tert-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate(1202760-30-2)

Safety Data

• Hazardous Substances Data: 1202760-30-2(Hazardous Substances Data)

Upstream product

• 36082-50-5 2,4-dichloro-5-bromopyrimidine 
• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 

Downstream Products

• 1202760-31-3 C₂₄H₂₈BrN₅O₄ 
• 1202760-32-4 C₂₅H₂₈N₆O₄ 
• 1202757-18-3 N-(3-(5-cyano-2-(6-methoxypyridin-3-ylamino)pyrimidin-4-ylamino)phenyl)acrylamide 
• 1429497-57-3 N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide 

Relevant articles and documents

Novel pyrimido-heterocyclic compound and preparation method and application thereof

The invention discloses a novel pyrimido-heterocyclic compound and a preparation method and application thereof. The structure of the pyrimido-heterocyclic compound disclosed by the invention is as shown in a general formula I, and the definitions of all substituents are described in the specification and claims. The pyrimido-heterocyclic compound disclosed by the invention has much better inhibitory activity and selectivity for double-mutant EGFR kinase than the existing AZD-9291, can be used for preparing anti-tumor drugs, and overcomes the defect of drug tolerance of the first generation ofEGFR inhibitor.

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties

Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.

C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant

The development of specific kinase inhibitors has been a long-standing challenge in chemical biology and drug discovery. We have successfully discovered a series of C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific inhibitors against the clinical resistance-related EGFRT790M mutant. One of the most promising compounds, 9f, tightly binds to the EGFRT790M mutant and strongly inhibits its enzymatic function with an IC50 value of 0.80 nM, and displays an extraordinary target specificity with S(35) and S(10) selectivity scores of 0.005 and 0.000, respectively, in a kinase selectivity profiling study against 456 different kinases at 100 nM. The compound also selectively suppresses the proliferation of EGFRT790M mutated H1975 NSCLC cells with an IC50 value of 2.80 nM, but is significantly less toxic to cells with wild-type EGFR. Compound 9f may serve as a promising lead compound for drug discovery overcoming the acquired resistance of NSCLC patients without adverse toxicities.